Search results
Results from the WOW.Com Content Network
Diabetes treatment Mounjaro has been on the health regulator's shortage list since late 2022, while weight-loss drug Zepbound was added in April as demand far outstripped supply. The limited ...
The FDA's decision is a win for Lilly, the drug's manufacturer, according to the Associated Press, prices and ways to access drugs like Zepbound and Mounjaro could be affected as a result of the move.
Lilly's drug, tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight management, will cease to be in shortage "very soon," CEO David Ricks said in an interview with Bloomberg in Paris.
Tirzepatide is the key ingredient in Lilly's blockbuster weight-loss drug Zepbound and diabetes drug Mounjaro. The FDA's decision starts a countdown clock of about 60 days, or until February, for ...
A news release from Eli Lilly in June 2024 outlines some concerns surrounding compounded versions of tirzepatide (the active ingredient in Mounjaro and Zepbound), some of which contained bacteria ...
(Reuters) -All doses of Eli Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro are now available, the U.S. Food and Drug Administration's updated shortage list showed on Friday. However ...
Eli Lilly and Co. on Thursday warned against use of its popular diabetes and weight loss drugs Mounjaro and Zepbound for “cosmetic” reasons. The news comes as rampant demand for the reputed ...
Lilly shares have rallied over 60% this year to make it the world's most valuable healthcare company by market cap as investors bet on Mounjaro's success. They were up 1.5% in choppy premarket ...